JPH044293B2 - - Google Patents

Info

Publication number
JPH044293B2
JPH044293B2 JP56061541A JP6154181A JPH044293B2 JP H044293 B2 JPH044293 B2 JP H044293B2 JP 56061541 A JP56061541 A JP 56061541A JP 6154181 A JP6154181 A JP 6154181A JP H044293 B2 JPH044293 B2 JP H044293B2
Authority
JP
Japan
Prior art keywords
drug
wall
compartment
formulation
passageway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP56061541A
Other languages
English (en)
Other versions
JPS56167617A (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPS56167617A publication Critical patent/JPS56167617A/ja
Publication of JPH044293B2 publication Critical patent/JPH044293B2/ja
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • External Artificial Organs (AREA)
  • Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Description

【発明の詳細な説明】 本発明は、医薬を人体のような流体環境に排出
する浸透性医薬製剤に関する。
医薬を胃腸管に排出するための、錠剤の形で製
造される浸透性医薬製剤は、フエリツクステーウ
エス(Felix Theeuwes)とタケルヒグチ
(Takeru Higuchi)の両者に付与されたアメリ
カ国特許第3845770号及び同第3916899号明細書で
公知である。これらの特許明細書に示されている
典型的な医薬製剤は医薬を含有している区画室を
包囲している半透性壁から成つている。この半透
性壁は、外部流体に対しては透過性であるが、医
薬の通過に対しては実質的に不透過性である。こ
の半透性壁には、これを貫通して系から医薬を排
出するための通路がある。系は、流体が半透性壁
を通つて区画室に壁の透過性と壁を横切る浸透圧
の圧力勾配によつて決まる速度で連続浸透して可
溶性の医薬を含有する溶液を形成し、この溶液を
系から時間の経過に沿つて分配することによつて
医薬を放出する。
フエリツクステーウエスに付与されたアメリカ
国特許第4036228号明細書において、特許権者は、
排出困難な医薬、特に水性タイプの流体に実際上
不溶性である医薬を排出する浸透性医薬製剤を開
示している。この製剤は、これに酸性成分と塩基
性成分から成る起泡性カツプルを満たすことによ
つて使用される。作用下においてその製剤が流体
環境中にあると、その起泡性カツプルは、流体を
製剤に浸透させ、それによつてカツプルを湿潤
し、反応させ、そして起泡性溶液を製剤内に生成
させる。起泡性溶液は製剤内に中性状態を作り出
し、そしてその医薬を製剤から分配する。このア
メリカ国特許は、それ自体酸性環境中で限定され
た溶解性を示す医薬の排出、塩基性成分だけの使
用及び使用環境における起泡の生成には指向して
いない。
本発明は、多くの抗炎症剤が浸透性医薬製剤か
ら制御された速度で排出するのは困難であるとい
うことの発見にある。抗炎症剤は、胃液のような
水性の酸性環境において溶解性が乏しく、従つて
これら医薬は、浸透性医薬製剤からの排出時に胃
液と接触して沈殿する。この現象は、医薬製剤の
半透性壁の通路出口においてその外表面に起こ
り、そこに医薬を沈殿、蓄積させる。沈殿した医
薬は、浸透性製剤の通路を通る溶液の流れを妨害
する。本発明は、医薬を二酸化炭素生成化合物と
混合することによつてその医薬を排出するもので
ある。ここで、前記化合物は、製剤からの放出時
及び胃領域中の酸との接触時に酸と反応し、二酸
化炭素ガスを生成させるものである。この物理作
用とガスは、付随的に医薬製剤の通路を開放に保
ちながら、医薬を細かく分散した形で医薬製剤か
ら分配する。
本発明を図面を参照して説明すると、第1図は
医薬を排出するのに用いられる浸透性医薬製剤1
0を説明するものである。浸透性医薬製剤10
は、切欠部に見られる通り、区画室12を包囲、
形成している半透性重合体から形成される壁11
から成る。壁11には、それを貫通して通路13
があり、該通路13を介して区画室12を医薬製
剤10の外面と接続させ、医薬製剤10から点で
表される医薬14とダツシユで表され、二酸化炭
素生成基を有する塩基性化合物15とを排出する
ようになつている。
第2図は医薬を排出するのに用いられる浸透性
医薬製剤10を説明するものであるる。この浸透
性医薬製剤は、切欠部に見られる通り、区画室1
2の内側に面している微孔質単層16を積層して
有する半透性重合体から形成される壁11から成
つている。図示しないが、もう1つの実施態様に
おいて、微孔質単層16は半透性壁11の外表面
にあることもできる。第2図において、装置10
は壁11と微孔質単層16によつて形成される半
透性微孔質積層体を貫通して通路13を有し、該
通路13を介して区画室12を製剤10の表面と
接続させ、医薬14及び二酸化炭素生成化合物1
5を製剤10から排出するようになつている。
浸透性医薬製剤10の半透性壁は、医薬、二酸
化炭素生成化合物又は病人に悪影響を及ぼさない
半透性物質から形成される。この半透性壁は水及
び生物の流体のような外部流体の通過に対しては
透過性であるが、医薬、溶質などの通過に対して
は本質的に不透過性である重合体物質から形成さ
れる。本発明の製剤を製造するのに有用な選択透
過性の重合体として、セルロースアクリレート、
セルロースジアクリレート、セルローストリアク
リレート、セルロースアセテート、セルロースジ
アセテート、セルローストリアセテート、ポリア
ミド、ポリウレタンなどより成る群から選ばれる
重合体が挙げられる。浸透性医薬製剤の製造に適
当な半透性重合体は、アメリカ国特許第3845770
号、同第3916899号、同第4008719号、同第
4036228号及び同第4111210号明細書に開示されて
いる。第2図に示される実施態様において、半透
性壁11は、微孔質単層16と層状配置の関係に
ある半透性単層11から成る積層体であることが
できる。半透性単層11は上記の重合体から形成
される。微孔質単層16は、多数の微孔と製剤に
流体を通す連続微孔路を有する。微孔質単層は、
製剤が使用環境中で作用下にあるとき単層から溶
出又は浸出する細孔形成剤が入つている前記重合
体から成つていることができる。細孔形成剤は無
毒性で、且つ壁を形成している物質と反応しない
ものである。これら細孔形成剤がその単層から除
去されると、その中に微孔路ができ、流体を満た
し、従つて、これら微孔路は、流体を医薬製剤に
入れる手段となる。典型的な細孔形成剤として、
塩化ナトリウム、塩化カリウム、ソルビトール、
マンニトール、ポリエチレングリコール、ヒドロ
キシプロピルメチルセルロース、ヒドロキシプロ
ピルブチルセルロースなどの物質が挙げられる。
半透性単層及び微孔質単層から成る積層壁を有す
る浸透性医薬製剤は、アメリカ国特許第4160452
号明細書に開示されている。
本発明において広範に用いられている医薬とい
う表現には、浸透性医薬製剤から排出して有利且
つ有用な結果を生むことができる任意の化合物、
物質の組成物又はそれらの混合物が包含される。
医薬という用語についてさらに明確に述べると、
これには動物、鳥類、魚類及びは虫類に局所的又
は全身的効果を生む任意の物質が包含される。動
物という用語は山羊、牛、馬、犬、ねこなどのよ
うな霊長類、人間、家畜、愛がん動物及び農放牧
動物を包含する。動物という用語はまたマウス、
ラツト及びモルモツトのような実験動物も包含す
る。本発明の方法によつて排出することができる
医薬には中枢神経系作用剤、催眠剤、鎮静剤、精
神神経賦活剤、トランキライザー、抗抑制剤、鎮
痙剤、筋弛緩剤、抗パーキンソン剤、麻酔剤、抗
炎症剤、局所麻酔剤、抗マラリア剤、ホルモン
剤、交感神経興奮剤、利尿剤、駆虫剤、ネオプラ
スチツクス、低血糖症剤、興奮剤、栄養剤のよう
な無機及び有機医薬がある。さらに好ましい実施
態様において、医薬という用語は中性及び酸性環
境に実際上不溶である、すなわち限定された溶解
性を持つ医薬を包含する。すなわち、これらの医
薬はこのような環境中で沈殿するのである。中性
という表現は水及び同様の生物環境を含み、また
酸という表現は胃及びその中に生成する塩酸、腟
及びその中に生成する乳酸などを含む。本明細書
において用いられている酸性体液という熟語は胃
液、腟液などの酸環境を指している。
本発明の方法により、上記環境に排出するのに
適当な医薬の1つの特定の群は、酸性抗炎症剤で
ある。抗炎症剤としては、アリールカルボン酸剤
及びエノル酸剤が挙げられる。アリールカルボン
酸剤の例には、アルクロフエナツク、すなわち、
4−アリルオキシ−3−クロロ−フエニル酢酸;
アスピリン、すなわち、アセチルサリチル酸;フ
エノプロフエン、すなわち、dl−2−(3−フエ
ノキシフエニル)プロピオン酸;フルフエナミン
酸、すなわち、2−(3−トリフルオロメチルア
ニリノ)安息香酸;イブプロフエン、すなわち、
2−(4−イソブチルフエニル)プロピオン酸;
インドメタシン、すなわち、5−メトキシ−2−
メチル−1−(4′−クロロベンゾイル)−3−イン
ドール−酢酸;ケトプロフエン、すなわち、2−
(3−ベンゾイルフエニル)プロピオン酸;メチ
アジニン酸、すなわち、10−メチル−2−フエノ
チアジニル酢酸;ナプロキセン、すなわち、d−
2−(6′−メトキシ−2′−ナフチル)プロピオン
酸;ニフルミン酸、すなわち、3−トリフルオロ
メチル−2−フエニル−アミノニコチン酸;トル
メチン、すなわち、1−メチル−5−p−トルオ
イルピロール−2−酢酸;及びサリンダツク、す
なわち、シス−5−フルオロ−2−メチル−1−
〔p−(メチルスルフイニル)−ベンジリデン〕イ
ンデン−3−酢酸がある。エノル酸剤の例には、
アザプロパゾン、即ち、3−ジメチルアミノ−7
−メチル−1,2−(n−プルピルマロニル)−1
−2,ジヒドロ−1,2,4−ベンゾトリアジ
ン;フエニルブタゾン、即ち、3,5−ジオキソ
−4−n−ブチル−1,2−ジフエニルピラゾリ
ジン;プレナゾン、すなわち、4−プレニル−
1,2−ジフエニル−3,5−ピラゾリジンジオ
ン;サドキシカム、すなわち、4−ヒドロキシ−
2−メチル−N−(2−チアゾリル)−2H−1,
2−ベンゾチアジン−3−カルボキサミド−1,
1−ジオキシドなどの化合物がある。他の抗炎症
剤には、ジクロフエナツク、すなわち、2−〔2,
6−ジクロロフエニル)アミノ〕ベンゼン酢酸;
及びペルオキシカム、すなわち、2H−1,2−
ベンゾチアジン−3−カルボキサミドがある。
本発明の方法によつて排出することができる、
水に実際上不溶の、又は水に極めてわずかしか溶
解しない他の医薬の例には、ジフエニドール、メ
クリジン塩酸塩、プロクロルペルアジンマレエー
ト、アニシンドン、ジフエナジオーン、エリトリ
チルテトラナイトレート、ジゾキシン、レスパー
ピン、アセタゾールアミド、メタゾールアミド、
ベンドロフルメチアジド、クロルプロパミド、ト
ラザミド、アロプリノール、アルミニウムアスピ
リン、サリチル酸、サリチル酸ナトリウム、サリ
チルアミド、アセトアミノフエン、アセトフエネ
チジン、コルヒチン、メフエナミン酸、オクスフ
エンブタゾン、ゾメピラツク、メソトレキセー
ト、アセチルスルフイソキサゾール、ヒドロコー
チゾン、デスオキシコルチコステロンアセテー
ト、コルチソンアセテート、トリアミノロン、17
−エストラジオール、17−ヒドロキシプロゲステ
ロン、19−ノルプロゲステロン、プレドニソロ
ン、プロゲステロン、ノルエチンドロンアセテー
ト、ノルエチノドレルなどの化合物がある。
医薬製剤中に存在する医薬の量は、ホストに投
与すべき医薬の活性と量に応じて変わる。一般
に、この製剤は、0.5mg〜3g、又はそれ以上の
医薬を含み、例えば、個々の製剤は25mg、50mg、
125mg、250mg、1.5gなどの量で医薬を含有して
いる。医薬は、分散体、顆粒、粉末、圧縮塊、フ
イルムなどの形態のような各種形態で製剤中に存
在することができる。また、医薬は結合剤、希釈
剤、分散剤、安定剤、染料などの添加剤と混合す
ることができる。有利な医薬、それらの溶解性、
それらの投与量は、マツクパブリツシング社
(Mack Publishing Co.)(イーストン
〔Easton〕、ペンシルバニア〔Penna〕)刊行のレ
ミングトン(Remington)著「フアーマシユー
テイカル サイエンセス(Pharmaceutical
Sciences)」第15版 (1975年);サウンダー社(Saunder Company) (フイラデルフイア〔Philadelphia〕、ペンシル
バニア)刊行のフアルコナー(Falconer)他著
「ザ ドラツグ、ザ ナース、ザ ペーシヤント、
インクルーデイング カレント ドラツグ ハン
ドブツク(The Drug,the Nurse,the
Patient,Including Current Drug Handbook)」
(1974〜1976年);メデイカル エコノミツクス社
(Medical Economics Co.)(オラデル
〔Oradell〕、ニユージヤージー〔N.J.〕)刊行の
「フイジシアン デスク レフアレンス
(Physician Desk Reference)」第33版(1979
年)、「アン オブ アラージー(Ann.of
Allergy)」第41巻、第75〜77ページ(1979年);
「アルゼニム フオルシユ(Arzenim.Forsch.)」
第25巻、第1629〜1635ページ(1975年);及びJ.
Inter.Med.Res.第7巻、第335〜338ページ(1979
年)においてこの技術分野に知られている。
本発明の目的に適当なガス生成化合物は、製薬
上許容でき、そしてa)半透性壁を横切つて濃度
勾配を示し、且つ医薬製剤中に流体を浸透させ、
b)緩衝剤として作用し、且つ医薬製剤に入つて
くる流体に溶解して医薬を含有する溶液を形成
し、c)医薬製剤の外側において通路を囲む隣接
区域のPHを医薬の沈殿速度を下げるのに十分高い
値まで上昇させ、そしてd)医薬製剤の外側で、
通路の環境界面においてその環境の酸と反応し
て、医薬を細かく分散した形で医薬製剤から放出
させる二酸化炭素の起泡を生成させる固体の塩基
性化合物が好ましい。この塩基性化合物には、ア
ルカリ金属炭酸塩及び重炭酸塩、アルカリ土類金
属炭酸塩及び重炭酸塩、並びにそれらの混合物の
ような無毒性の金属炭酸塩及び重炭酸塩がある。
好ましい化合物は、水に可溶で、且つ環境の酸と
接触して速やかに起泡を生成するものである。水
中での溶解度が異なる化合物の混合物を水に非常
によく溶解しうる少なくとも1種の化合物ととも
に使用することもできる。典型的化合物として炭
酸リチウム、炭酸ナトリウム、炭酸カリウム、重
炭酸リチウム、重炭酸ナトリウム、重炭酸カリウ
ム、炭酸マグネシウム、炭酸カルシウム、重炭酸
マグネシウムなどの塩がある。炭酸アンモニウ
ム、重炭酸アンモニウム、セスキ炭酸アンモニウ
ム、セスキ炭酸ナトリウムなどの塩も有用なガス
生成化合物である。これらの化合物は、水に溶解
するとき7より大きいPH、通常8と12の間のPHを
示す。任意であるが、共通イオン効果のない医薬
とガス生成化合物を選ぶのがしばしば望ましく、
かくして医薬製剤に入つてくる流体中のそれらそ
れぞれの溶解度は最大になる。区画室に収容され
る塩基性化合物又はその混合物の量は一般に約
0.5mg〜3g、又はそれ以上、好ましくは25〜750
mgである。塩基性化合物及びそれらの水中におけ
る溶解度についてはケミカル ラバー社
(Chemical Rubber Co.)(クリーブランド
〔Cleveland〕、オハイオ〔Ohio〕)刊行の「ザ
ハンドブツク オブ ケミストリー アンド フ
イジツクス(The Handbook of Chemistry
and Physics)」第48版(1968年)に開示されて
いる。
医薬及び塩基性化合物は、また、結合剤及び潤
滑剤として用いることができる。医薬及び塩基性
化合物は、水溶性結合剤に混合されるか、又は水
と接触すると医薬及び塩基性化合物を放出する水
不溶性結合剤に混合される。典型的な水溶性結合
剤には、ポリ(エチレングリコール)、ゼラチン、
寒天、カルボキシセルロース、エチルメチル−セ
ルロース、ポリ(ビニルアルコール)、ポリ(ビ
ニルピロリドン)、水溶性殿粉誘導体などがある。
典型的な潤滑剤には、ステアリン酸、ステアリン
酸マグネシウム、ステアリン酸亜鉛などがある。
使用される結合剤及び潤滑剤の量は一般に約0.1
〜150mg、又はそれ以上である。
本発明の浸透性医薬製剤は、標準的な方法で製
造される。例えば、1つの実施態様において、医
薬を塩基性化合物及び他の成分と、ボールミルで
粉砕し、カレンダリングし、撹拌し、そして所定
の形状にプレス成形することによつて混合する。
医薬製剤の壁を形成する物質は、浸漬、モールデ
イング又は噴霧によつて、プレス成形された混合
物に適用することができる。壁を適用する1つの
方法は空気懸濁法である。空気懸濁法は、単層か
ら、又は複雑層から形成される壁を作るのに用い
ることができる。空気懸濁法は、アメリカ国特許
第2799241号;J.Am.Pharm.Assoc.第48巻、第
451〜459ページ(1959年);及び同第49巻、第82
〜84ページ(1960年)に記載されている。壁を貫
通する浸透通路又は孔は機械的にドリリングする
か、レーザーでドリリングするか、パンチングす
るか、又はダイで切ることによつて作られる。レ
ーザーを用いて通路を形成する方法はアメリカ国
特許第3916899号及び同第4088864号明細書に記載
されている。他の標準的な製造方法は「モダーン
プラスチツク エンサイクロペデイア
(Modern Plastic Encyclopedia)」第46巻、第62
〜70ページ(1969年);マツク パブリツシング
社(イーストン、ペンシルバニア)刊行の、「レ
ミングトンズ フアーマシユーテイカル サイエ
ンセス」第14版、第1649〜1698ページ(1970
年);及びリー アンド フエビガー社(Lea
& Febiger Co.)(フイラデルフイア
〔Philadelphia〕、ペンシルバニア〔Penn.〕)刊行
のラチマン(Lachman)他著「ザ セラピー
アンド プラクテイス オブ インダストリアル
フアーマシー(The Therapy and Practice
of Industrial Pharmacy)第197〜225ページ
(1970年)に記載されている。
次の実施例は本発明を単に説明するだけのもの
であり、いずれの点でも本発明の範囲を限定する
ものと考えるべきでない。
実施例 1 非ステロイド系抗炎症剤のインドメタシンナト
リウムの排出のための経口浸透性医薬製剤を次の
ようにして製造した。医薬製剤の区画室にいれる
ための医薬組成物を、105.2mgのインドメタシン
ナトリウム三水和物、142mgの重炭酸カリウム、
5.0mgのポリビニルピロリドン及び7.1mgのステア
リン酸を完全に配合し、次いでその均質な配合物
を予備区画室形成用医薬調合物に圧縮成形するこ
とによつて調製した。次に、圧縮成形した医薬調
合物を空気懸濁機に入れ、微孔質単層形成組成物
を被覆した。微孔質単層組成物は、45重量%の、
アセチル含量が39.8%のセルロースアセテート、
27.5重量%のヒドロキシプロピルメチルセルロー
ス及び27.5重量%のポリエチレングリコール4000
から成つていた。微孔質単層は、塩化メチレン−
95%エタノール溶剤(80:20、重量:重量)から
形成した。微孔質単層は厚さ5ミルであつた。
次に、半透性外層を空気懸濁機中で微孔質単層
の上に積層した。半透性層形成組成物は50重量%
の、アセチル含量が39.8%のセルロースアセテー
ト及び50重量%の、アセチル含量が32%のセルロ
ースアセテートから成つていた。半透性単層は塩
化メチレンと95%エタノールから成る混合溶剤
(80:20、重量:重量)から適用した。この系を
乾燥し、そして10ミルの通路を積層壁を貫通して
レーザーでドリリングした。この系は、インドメ
タシンを8mg/時間の速度で放出する。この医薬
製剤は作用下において通路出口端で酸性胃液と接
触すると、医薬をケバ状態で分散させる二酸化炭
素の気泡を生成させて起泡する溶液を放出する。
実施例 2 インドメタシンを制御して連続排出する経口浸
透性医薬製剤を前記の一般的操作を行うことによ
つて作つた。本製剤において、区画室は56.4%の
炭酸カリウム、37.6%のインドメタシンナトリウ
ム三水和物、3%のプロビドン (Providone
)及び3%のステアリン酸から成る医薬調合物
を収容していた。圧縮成形後の調合物は、直径
7.93mm、面積1.6cm2及び密度1.65g/mlを有してい
た。製剤は45重量%の、アセチル含量が39.8%の
セルロースアセテート、45重量%のソルビトール
及び10重量%のポリエチレングリコール400から
本質的に成る微孔質内層を含む積層された壁を有
していた。内層は塩化メチレン−メタノール−水
(62:35:3重量比)から成る溶剤から適用した。
この微孔質単層の上に半透性層を積層した。半透
性層は50重量%の、アセチル含量が39.8%のセル
ロースアセテート及び50重量%の、アセチル含量
が32%のセルロースアセテートから成つている。
半透性層は塩化メチレンとメタノール(80:20重
量比)から成る溶剤から適用した。微孔質形成層
は、厚さ5ミルで、半透性層は厚さ2.4ミルであ
つた。この製剤は、9ミルの通路を有し、インド
メタシンを8mg/時間の速度で排出した。この製
剤は、通路の環境界面において、及び通路付近の
製剤の壁の上において急速な沈殿を実質的に起こ
さずに医薬を排出する。
実施例 3 微孔質形成単層が厚さ1ミル、半透性単層が厚
さ2.7ミルで、医薬の放出速度が8mg/時間であ
る点を除いて実施例2に記載の条件を用いて実施
例2の操作を繰り返した。
実施例 4 (a)微孔質単層が厚さ5ミル、半透性単層が厚さ
3.4ミル及び医薬製剤の医薬放出速度が6mg/時
間である、及び(b)微孔質単層が厚さ5ミル、半透
性単層が厚さ1.7ミル及び系の医薬放出速度が12
mg/時間である実施例1及び2の浸透性医薬製剤
を本実施例で製造した。
実施例 5 胃腸管中でアリールカルボン酸系抗炎症剤を放
出する一連の経口浸透性医薬製剤を本発明に従つ
て調製する。この製剤は、40〜250mgのインドメ
タシンナトリウム、好ましくは85〜125mgのイン
ドメタシンナトリウム三水和物(これは70〜100
mgのインドメタシンに相当する)、50〜300mg、好
ましくは130〜190mgの重炭酸カリウム、2〜20
mg、好ましくは5〜10mgの結合剤及び2〜20mg、
好ましくは5〜10mgの潤滑剤を収容する。この製
剤は、0.10〜0.16mmの厚さを持つ18〜25mgの重さ
の内側微孔質形成単層と0.035〜0.100mmの厚さを
持つ6〜20mgの重さの外側半透性単層を有する。
この製剤は0.18〜0.38mmの通路を有し、医薬を5
〜15mg/時間の速度で放出する。
本発明により生まれる予期されない利点は第3
図及び第4図に認められる。第3図はガス生成塩
基性化合物なしで製造した浸透性医薬製剤からの
インドメタシンの放出を示している。この製剤
は、塩酸を含有する人工胃液の存在下で医薬を放
出するが、しかしながら医薬は製剤の壁及び通路
の出口部に沈殿し、従つて医薬は環境の流体中に
は認められない。医薬は第3図に示されるように
時間基準で分析されている。第4図は、塩基性の
ガス生成化合物により製造した浸透性医薬製剤か
らのインドメタシンの放出を示している。この製
剤は作用下において本発明による両人工胃腸管液
に医薬を放出する。
【図面の簡単な説明】
第1図は、縮尺して製図したものでないが、医
薬を排出するのに用いられ、半透性壁によりつく
られた浸透性医薬製剤の切欠図であり、第2図
は、縮尺して製図したものでないが、医薬を排出
するのに用いられる、微孔質半透性壁により作ら
れた浸透性医薬製剤の切欠図であり、第3図は、
浸透性医薬製剤からガス生成化合物なしで放出さ
れる貧溶解性医薬の放出パターンを示すグラフで
あり、そして第4図は、浸透性医薬製剤からガス
生成化合物とともに放出される貧溶解性医薬の放
出パターンを示すグラフである。 10…浸透性医薬製剤、11…半透性壁、12
…区画室、13…通路、14…医薬、15…塩基
性化合物、16…微孔質単層。

Claims (1)

    【特許請求の範囲】
  1. 1 流体の通過に対しては透過性であるが、医薬
    の通過に対しては実質的に不透過性である半透性
    の重合体壁、この壁によつて包囲、形成された区
    画室および前記壁中に形成された前記医薬を排出
    するための通路から成り、前記区画室は、酸流体
    環境で沈殿する医薬と、二酸化炭素生成基を有す
    る非毒性塩基性化合物を含み、該塩基性化合物は
    区画室中に吸収される流体に可溶性であり、か
    つ、この流体に対して前記の壁を横切つて浸透圧
    の圧力勾配を示す、医薬を酸流体環境に排出する
    ための浸透性医薬製剤において、該医薬製剤の外
    側で該塩基性化合物を該酸流体環境と反応させる
    ことにより、通路の出口でガスを発生させ、泡立
    ちを生じさせ該通路の出口で医薬の沈殿を少なく
    することを特徴とする、通路の出口と酸流体環境
    の界面における医薬の沈殿を少なくするように改
    良された浸透性医薬製剤。
JP6154181A 1980-04-25 1981-04-24 Permeation device Granted JPS56167617A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/143,644 US4265874A (en) 1980-04-25 1980-04-25 Method of delivering drug with aid of effervescent activity generated in environment of use

Publications (2)

Publication Number Publication Date
JPS56167617A JPS56167617A (en) 1981-12-23
JPH044293B2 true JPH044293B2 (ja) 1992-01-27

Family

ID=22504961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6154181A Granted JPS56167617A (en) 1980-04-25 1981-04-24 Permeation device

Country Status (11)

Country Link
US (1) US4265874A (ja)
EP (1) EP0040899B1 (ja)
JP (1) JPS56167617A (ja)
AT (1) ATE9267T1 (ja)
DE (1) DE3165901D1 (ja)
DK (1) DK152482C (ja)
ES (2) ES267593Y (ja)
GR (1) GR73519B (ja)
IE (1) IE51216B1 (ja)
NZ (1) NZ196561A (ja)
PT (1) PT72796B (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150137871A (ko) * 2014-05-30 2015-12-09 디씨에스이엔지 주식회사 회전속도비를 이용하여 회전체내 절삭툴을 제어할 수 있는 오비탈식 파이프 절삭장치

Families Citing this family (713)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US4344929A (en) * 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
FR2525474A1 (fr) * 1982-04-26 1983-10-28 Roussel Uclaf Nouvelle forme pharmaceutique orale de clometacine
US4478596A (en) * 1982-11-26 1984-10-23 Michelson Paul E Delivery system for physiologically active agents
US4613330A (en) * 1982-11-26 1986-09-23 Michelson Paul E Delivery system for desired agents
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
JPH075457B2 (ja) * 1983-08-16 1995-01-25 ザ ウエルカム フアウンデ−シヨン リミテツド 調節された方法による有効成分の放出を可能にする医薬組成物
US4670578A (en) * 1983-08-29 1987-06-02 Merck & Co., Inc. Process for crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters
EP0137364A3 (en) * 1983-09-23 1986-10-22 Merck & Co. Inc. Suppository form of an osmotic therapeutic system
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
GB2150434B (en) * 1983-12-01 1987-11-04 Alza Corp Constant rate release systems
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
US4725427A (en) * 1984-03-13 1988-02-16 Albion International, Inc. Effervescent vitamin-mineral granule preparation
US4717566A (en) * 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
US4595583A (en) * 1984-03-19 1986-06-17 Alza Corporation Delivery system controlled administration of beneficial agent to ruminants
EP0166354B1 (en) 1984-06-26 1992-08-05 Merck & Co. Inc. Benzofused lactam compounds and pharmaceutical compositions containing them
US4693895A (en) * 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US4627971A (en) * 1985-04-22 1986-12-09 Alza Corporation Osmotic device with self-sealing passageway
US4675174A (en) * 1985-08-16 1987-06-23 Alza Corporation Veterinary dispenser delivering beneficial agent by gas power generated in situ
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
US4847093A (en) * 1986-06-19 1989-07-11 Alza Corporation Dosage form with means for governing rate of gas formation
US5143908A (en) * 1986-11-05 1992-09-01 Merck & Co., Inc. Antibacterial agents and potentiators of carbapenem antibiotics
US5099063A (en) * 1986-11-05 1992-03-24 Merck & Co., Inc. Certain phosphinic acid derivatives having antibacterial activity
US4715994A (en) * 1986-11-05 1987-12-29 Merck & Co., Inc. Novel antibacterial agents and potentiators of carbapenem antibiotics
US4957494A (en) * 1987-06-25 1990-09-18 Alza Corporation Multi-layer delivery system
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5499979A (en) * 1987-06-25 1996-03-19 Alza Corporation Delivery system comprising kinetic forces
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US5041644A (en) * 1987-07-06 1991-08-20 Merck & Co., Inc. Peptide derivatives of β-chloro-L(Z)-dehydro-glutamic acid
JPS6413097A (en) * 1987-07-06 1989-01-17 Mitsubishi Chem Ind Phosphonic acid derivative
DE3873278T2 (de) 1987-09-22 1993-02-25 Merck & Co Inc Aryl-substituierte thiophen-3-ole, ihre derivate und analoge als lipoxygenase-inhibitoren.
US5030732A (en) * 1988-03-03 1991-07-09 Merck & Co., Inc. Aminoethylphosphinic acid derivatives
CH675537A5 (ja) * 1988-03-25 1990-10-15 Ciba Geigy Ag
US5211957A (en) * 1988-03-25 1993-05-18 Ciba-Geigy Corporation Solid rapidly disintegrating dosage form
US5145990A (en) * 1988-10-28 1992-09-08 Merck & Co., Inc. Phosphorous containing dhp enzyme inhibitors
US5147867A (en) * 1988-10-28 1992-09-15 Merck & Co., Inc. Phosphorus containing enzyme inhibitors
US4962097A (en) * 1988-10-28 1990-10-09 Merck & Co., Inc. Method of treating bacterial infection with phosphorus containing DHP enzyme inhibitors
US4942039A (en) * 1989-05-09 1990-07-17 Miles Inc. Effervescent analgesic antacid composition having reduced sodium content
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5089530A (en) 1990-08-03 1992-02-18 Merck & Co., Inc. Novel fermentation product with antiparasitic activity
US5443459A (en) * 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
SG84487A1 (en) 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5639782A (en) * 1992-03-04 1997-06-17 Center For Innovative Technology Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors
AU666578B2 (en) 1992-07-13 1996-02-15 Cytomed, Inc 2,5-diaryl tetrahydro-thiophenes, -furans and analogs for the treatment of inflammatory and immune disorders
US5463083A (en) 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5434151A (en) * 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5498255A (en) * 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
US5403952A (en) * 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
US5750565A (en) * 1995-05-25 1998-05-12 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5703093A (en) * 1995-05-31 1997-12-30 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5792776A (en) * 1994-06-27 1998-08-11 Cytomed, Inc., Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US6348571B1 (en) 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
EP0827402A2 (en) * 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5817335A (en) * 1995-05-26 1998-10-06 Alza Corporation Osmotic device with high drug loading and delayed activation of drug delivery
US5756540A (en) * 1995-06-02 1998-05-26 Mcw Research Foundation, Inc. Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5800422A (en) * 1995-06-02 1998-09-01 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
US5741815A (en) * 1995-06-02 1998-04-21 Lai; Ching-San Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US6372713B1 (en) * 1995-09-08 2002-04-16 The Board Of Trustees Of Northwestern University Anti-depressant effects of corticotropin release inhibiting factor
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US6723531B2 (en) * 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
US5902605A (en) * 1996-04-18 1999-05-11 Alza Corporation Drug delivery device with minimal residual drug retention
US5785688A (en) * 1996-05-07 1998-07-28 Ceramatec, Inc. Fluid delivery apparatus and method
US5939460A (en) * 1996-07-08 1999-08-17 Idun Pharmaceuticals, Inc. Method of inhibiting NADPH oxidase
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5922761A (en) * 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
JP2002511837A (ja) 1996-09-10 2002-04-16 メデイノックス,インコーポレイテッド ポリジチオカルバメート含有マクロ分子と、治療及び診断用途へのその使用
US5858402A (en) * 1997-02-11 1999-01-12 Medinox, Inc. Methods for in vivo reduction of cyanide levels and compositions useful therefor
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
US7105496B2 (en) * 1998-07-23 2006-09-12 Northwestern University Methods and compositions for inhibiting angiogenesis
US6797691B1 (en) 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
CA2305703A1 (en) 1997-10-10 1999-04-22 David W. Christianson Compositions and methods for inhibiting arginase activity
US6358536B1 (en) 1997-10-15 2002-03-19 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US6750201B1 (en) * 1997-10-17 2004-06-15 The Trustees Of The University Of Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
US6756491B2 (en) 1998-01-09 2004-06-29 The Salk Institute For Biological Studies Steroid-activated nuclear receptors and uses therefor
US6984773B1 (en) 1998-01-09 2006-01-10 The Salk Institute For Biological Studies Transgenic mice expressing a human SXR receptor polypeptide
US6107274A (en) * 1998-03-16 2000-08-22 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
US6287605B1 (en) * 1998-04-17 2001-09-11 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treatment and prevention of HIV-1 infection
AU3979099A (en) 1998-05-11 1999-11-29 Philadelphia Health & Education Corporation (mct-1), a human oncogene
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US20050203187A1 (en) * 1998-06-01 2005-09-15 Verbiscar Anthony J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
US6265420B1 (en) 1998-06-23 2001-07-24 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
US6093743A (en) * 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6596770B2 (en) 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US20030064917A1 (en) * 1998-07-23 2003-04-03 Crawford Susan E. Methods and compositions for inhibiting angiogenesis
WO2000009118A1 (en) 1998-08-13 2000-02-24 The Wistar Institute Methods for reducing atherosclerotic plaques
US6565854B2 (en) 1998-08-13 2003-05-20 Philadelphia Health And Education Corporation Antimicrobial histone H1 compositions, kits, and methods of use thereof
US6646113B1 (en) * 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US20020138856A1 (en) * 1998-10-23 2002-09-26 Northwestern University Compositions and methods useful for treatment of depressive disorder based on an animal model
KR20010113642A (ko) 1999-01-13 2001-12-28 추후기재 약물의 효능을 증대시키기 위한 조성물 및 증대 방법
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6852704B1 (en) 1999-01-19 2005-02-08 The Children's Hospital Of Philadelphia Reverse gene therapy
US7282489B2 (en) * 2000-01-19 2007-10-16 The Children's Hospital Of Philadelphia Compositions and methods for performing reverse gene therapy
US7141417B1 (en) * 1999-02-25 2006-11-28 Thomas Jefferson University Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
AU764005B2 (en) 1999-02-25 2003-08-07 Merck Frosst Canada & Co. PDE IV inhibiting compounds, compositions and methods of treatment
US6221855B1 (en) 1999-03-11 2001-04-24 Wake Forest University Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
AU4803800A (en) 1999-04-27 2000-11-10 Trustees Of The University Of Pennsylvania, The Compositions, methods, and kits relating to LTiGTresistinLT/iGT
US6420545B1 (en) * 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
US7160694B2 (en) 1999-06-14 2007-01-09 Millennium Pharmaceuticals, Inc. Nucleic acids encoding TANGO405 and functional fragments and uses thereof
US7033780B1 (en) * 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US6964854B1 (en) 1999-07-13 2005-11-15 Science & Technology Corporation Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
AU782401B2 (en) 1999-10-08 2005-07-28 Taiji Biomedical, Inc. Methods of enhancing chemotherapy
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
JP4754143B2 (ja) 1999-10-12 2011-08-24 ケモセントリックス, インコーポレイテッド ケモカインレセプター
US6274627B1 (en) 1999-10-12 2001-08-14 Medinox, Inc. Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
JP3417370B2 (ja) 1999-12-09 2003-06-16 株式会社村田製作所 非可逆回路素子及び通信機装置
US6559128B1 (en) * 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
US20030212021A1 (en) * 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
JP2001320205A (ja) 2000-03-02 2001-11-16 Murata Mfg Co Ltd 非可逆回路素子および通信装置
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
MXPA02009943A (es) * 2000-04-07 2003-04-25 Univ Pennsylvania Analogos de tamandarin y didemnin y metodos para hacerlos y usarlos.
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
CA2409035A1 (en) 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic acid derivatives
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
WO2001091730A1 (en) 2000-05-31 2001-12-06 Drugtech Corporation Mineral supplement
US6833357B2 (en) * 2000-06-20 2004-12-21 The Trustees Of The University Of Pennsylvania Compositions and methods for modulating muscle cell and tissue contractility
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
EP1303536B1 (en) 2000-07-19 2010-03-17 Advanced Research And Technology Institute, Inc. Novel fibroblast growth factor (fgf23) and methods for use
AU2001290629A1 (en) * 2000-09-07 2002-03-22 Boehringer Ingelheim International G.M.B.H Heat shock response and virus replication
US7538097B2 (en) * 2000-09-26 2009-05-26 Halozyme, Inc. Inhibition of antigen presentation with poorly catabolized polymers
US20040102367A1 (en) * 2001-02-23 2004-05-27 Gage Fred H Gene expression system based on chimeric receptors
CN1494425B (zh) * 2001-03-05 2011-12-07 特兰斯泰克制药公司 用作治疗剂的羧酰胺衍生物
WO2002069965A1 (en) * 2001-03-05 2002-09-12 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
AU2002248557A1 (en) * 2001-03-05 2002-09-19 Transtech Pharma, Inc. High level insect expression of rage proteins
US7208279B2 (en) * 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
US7294472B2 (en) * 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6727287B2 (en) 2001-04-16 2004-04-27 Pts International, Inc. Toluene sulfonamide-containing anti-tumor composition and method of use thereof
US6632217B2 (en) * 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
CN1157388C (zh) * 2001-05-29 2004-07-14 北京大学 哌嗪基二硫代甲酸酯类化合物,它们的制备方法和在抗肿瘤药物中的应用
RU2259825C9 (ru) 2001-06-18 2006-04-10 БиоДием Лимитед Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2003007793A2 (en) * 2001-07-17 2003-01-30 Yale University Compositions, methods, and kits related to treating and diagnosing hypertension
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
GB0119396D0 (en) * 2001-08-09 2001-10-03 Celltech R&D Ltd Hydroxamic acid derivatives
CA2456977C (en) * 2001-08-16 2011-06-07 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
US9056048B2 (en) * 2001-08-16 2015-06-16 The Trustees Of The University Of Pennsylvania Synthesis and use of cationic steroids for anti-inflammatory drug therapy
US20050042303A1 (en) * 2001-08-27 2005-02-24 Brown Tracey Jean Therapeutic protocols
US20030069071A1 (en) * 2001-09-28 2003-04-10 Tim Britt Entertainment monitoring system and method
ES2266564T3 (es) * 2001-10-19 2007-03-01 Isotechnika Inc. Sintesis de analogos de cicloporinas.
US6555563B1 (en) 2001-11-16 2003-04-29 Medinox, Inc. Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation
US7413866B2 (en) * 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
JP2005518391A (ja) 2001-12-21 2005-06-23 ノボ ノルディスク アクティーゼルスカブ Gk活性化剤としてのアミド誘導体
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
US7378111B2 (en) * 2002-02-20 2008-05-27 The Trustees Of The University Of Pennsylvania Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
CN100525763C (zh) * 2002-03-05 2009-08-12 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
AU2003221706B2 (en) 2002-04-11 2008-02-28 Merck Sharp & Dohme Corp. 1H-Benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators
US7622117B2 (en) * 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
JP2005533013A (ja) * 2002-04-19 2005-11-04 イスム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティ オブ エルサレム 一酸化窒素供与基および反応性酸素種捕捉基を含有するβ作用薬化合物、ならびに呼吸障害の治療における該化合物の使用
EP1501511A4 (en) * 2002-05-06 2006-06-07 Univ Washington METHODS OF TREATING GLAUCOMA AND OTHER CONDITIONS INDUCED BY EXPRESSION OF NOS-2 BY INHIBITING THE EGFR PATHWAY
AUPS234402A0 (en) * 2002-05-15 2002-06-13 Auckland Uniservices Limited Anti-tumour polycyclic carboxamides
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
EP2402309A1 (en) * 2002-05-24 2012-01-04 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
WO2003105853A1 (en) 2002-06-12 2003-12-24 Chemocentryx, Inc. 1-aryl-4-substituted piperazines derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US6727241B2 (en) 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
US7589199B2 (en) * 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US20040077691A1 (en) * 2002-06-21 2004-04-22 Medinox, Inc. Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
US6620813B1 (en) 2002-06-21 2003-09-16 Medinox, Inc. Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
NZ539211A (en) 2002-10-04 2008-05-30 Prana Biotechnology Ltd Neurologically-active compounds
WO2004037206A2 (en) * 2002-10-23 2004-05-06 University Of Hawaii Methods for diagnosing and treating pre-term labor
EP1562975A2 (en) * 2002-10-25 2005-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
AU2003284984B2 (en) 2002-10-30 2008-10-23 Merck Sharp & Dohme Corp. Gamma-aminoamide modulators of chemokine receptor activity
ATE468114T1 (de) 2002-11-08 2010-06-15 High Point Pharmaceuticals Llc Sichere chemische entkuppler zur behandlung von fettsucht
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US7420055B2 (en) * 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
KR100874292B1 (ko) 2002-11-18 2008-12-18 케모센트릭스 아릴 술폰아마이드
US7227035B2 (en) * 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US20070021466A1 (en) * 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
KR100772297B1 (ko) * 2002-11-22 2007-11-02 니뽄 다바코 산교 가부시키가이샤 융합 비시클릭 질소-함유 헤테로사이클
EP1578413A2 (en) * 2002-11-29 2005-09-28 Yissum Research Development Company of The Hebrew University of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
AU2003295171B2 (en) 2002-12-20 2007-09-06 Arakis Ltd. Benzoxazocines and their use as monoamine-reuptake inhibitors
CA2511242C (en) * 2002-12-20 2010-01-12 Anita Melikian Inhibitors of human tumor-expressed ccxckr2
WO2004062597A2 (en) * 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
AU2003900927A0 (en) * 2003-02-28 2003-03-13 Biodiem Ltd Growth promotion method
JP2006523214A (ja) * 2003-03-21 2006-10-12 ジユーリー,マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
EP2239012A3 (en) 2003-04-11 2011-06-15 High Point Pharmaceuticals, LLC Substituted amide derivatives and pharmaceutical uses thereof
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
AU2004251599A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
EP1656372B1 (en) 2003-07-30 2013-04-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
JP2007501801A (ja) * 2003-08-07 2007-02-01 日本たばこ産業株式会社 ピロロ[1,2−b]ピリダジン誘導体
EP1653995A1 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
WO2005025513A2 (en) * 2003-09-12 2005-03-24 The Regents Of The Univeristy Of California Guanidinium derivatives for improved cellular transport
WO2005033297A1 (en) * 2003-09-19 2005-04-14 The Rockefeller University Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
WO2005030797A2 (en) 2003-09-30 2005-04-07 Novo Nordisk A/S Melanocortin receptor agonists
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US20100247540A1 (en) * 2003-10-30 2010-09-30 Chemocentryx, Inc. Methods and Compositions For Modulating Angiogenesis
WO2005058280A2 (en) * 2003-12-12 2005-06-30 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
CN1890221B (zh) * 2003-12-15 2014-07-16 沙拉麦斯实验公司 1-n-苯基-氨基-1h-咪唑衍生物和含有它们的医药组合物
ES2399052T3 (es) 2004-01-06 2013-03-25 Novo Nordisk A/S Heteroaril-ureas y su uso como activadores de glucocinasa
AU2005219438B2 (en) * 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
JP4773424B2 (ja) 2004-03-19 2011-09-14 イエール ユニバーシティ レナラーゼ(モノアミンオキシダーゼc)の検出、単離及び使用
US20060030611A1 (en) * 2004-03-22 2006-02-09 Myogen, Inc. Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
US20060025463A1 (en) * 2004-03-22 2006-02-02 Michael Bristow Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
BRPI0511748A (pt) * 2004-06-01 2008-01-02 Univ Virginia composição farmacêutica, métodos para tratar cáncer e uma doença ou distúrbio associado com angiogênese em um indivìduo em necessidade, para inibir a proliferação de células endoteliais vasculares e cancerosas, e para preparar sc-2-71 e análogos do mesmo, rótulo de fotoafinidade de sc-2-71, método para interromper a polimerização dos microtúbulos em uma célula, e para identificar um análogo, análogo, e, kit para administrar uma composiçaõ farmacêutica a um indivìduo
WO2005120495A1 (en) 2004-06-14 2005-12-22 Salama Zoser B Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
EP1776108A1 (en) * 2004-06-23 2007-04-25 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
JP5065019B2 (ja) * 2004-06-24 2012-10-31 ウィスコンシン アルムニ リサーチ ファンデイション 新生糖ランダム化及びジギトキシン類似体
US8507411B2 (en) * 2004-06-24 2013-08-13 Wisconsin Alumni Research Foundation Neoglycorandomization and digitoxin analogs
EP1765785B1 (en) * 2004-07-02 2009-07-08 Allergan, Inc. Prostaglandin analogs
MX2007001556A (es) * 2004-08-03 2008-03-05 Transtech Pharma Inc Proteinas de fusion del receptor para los productos finales glucados avanzados y metodos de uso.
US7906552B2 (en) 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101904B2 (en) * 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7183310B2 (en) * 2004-08-10 2007-02-27 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
EP1784179A4 (en) 2004-08-24 2010-03-31 Merck Sharp & Dohme COMBINATION THERAPY FOR THE TREATMENT OF CYCLOOXYGENASE-2-MEDIATED DISEASES OR CONDITIONS IN PATIENTS WITH RISK TO THROMBOTIC CARDIOVASCULAR EVENTS
KR20070054246A (ko) * 2004-09-17 2007-05-28 유니버시티 오브 매사추세츠 리소좀성 효소 결핍을 위한 조성물 및 이의 용도
AU2005292259A1 (en) * 2004-10-01 2006-04-13 Merck & Co., Inc. Compositions and methods for treating ophthalmic diseases
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
US7612082B2 (en) * 2004-10-28 2009-11-03 Allergan, Inc. Prostaglandin EP4 antagonists
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
WO2006058923A1 (en) 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
EP1855673A4 (en) * 2005-01-06 2008-03-12 Merck & Co Inc COMBINED THERAPY AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
ATE503741T1 (de) 2005-01-14 2011-04-15 Chemocentryx Inc Heteroarylsulfonamide und ccr2
TWI386208B (zh) * 2005-04-18 2013-02-21 Allergan Inc 治療性的經取代環戊酮
WO2006116319A2 (en) * 2005-04-21 2006-11-02 Chemocentryx, Inc. Reagents that bind ccx-ckr2
CA2605228A1 (en) 2005-04-27 2007-03-08 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
BRPI0611257A2 (pt) * 2005-05-06 2010-08-24 Allergan Inc beta-lactamas substituÍdas e uso em medicina do mesmo
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
PL1883394T3 (pl) 2005-05-23 2018-09-28 Sdg, Inc. Konstrukt lipidowy do dostarczania insuliny ssakowi
SG137989A1 (en) 2005-06-08 2008-01-28 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2612508A1 (en) * 2005-06-17 2006-12-28 Dynamis Therapeutics, Inc. Treatment of inflammatory conditions
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
US7799795B2 (en) 2005-06-27 2010-09-21 Amgen Inc. Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders
WO2007005176A1 (en) * 2005-06-29 2007-01-11 Allergan, Inc. Pyrrolidinones for the treatment of glaucoma and ocular hypertension
AU2006268589B2 (en) 2005-07-14 2011-09-29 Vtv Therapeutics Llc Urea glucokinase activators
CN103784960A (zh) * 2005-07-27 2014-05-14 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
MX2008002073A (es) 2005-08-12 2008-04-16 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios.
CA2620306A1 (en) 2005-08-25 2007-03-01 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
US8871764B2 (en) 2005-08-29 2014-10-28 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
CA2618970C (en) 2005-08-29 2015-03-31 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
CN101287475B (zh) 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
US20090209624A1 (en) * 2005-10-24 2009-08-20 University Of Massachusetts Compositions and their uses for gene therapy of bone conditions
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
ATE486875T1 (de) 2005-11-10 2010-11-15 Chemocentryx Inc Substituierte chinolone und verwendungsverfahren
US7427685B2 (en) 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
EP1965796A2 (en) * 2005-12-20 2008-09-10 Gilead Colorado, Inc. 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
US7323477B2 (en) * 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
CA2643299A1 (en) * 2006-02-21 2007-08-30 Astrum Therapeutics Pty. Ltd. Compositions to reduce blood glucose levels and treat diabetes
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
CA2645867A1 (en) 2006-03-20 2007-09-27 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists
US20070225246A1 (en) * 2006-03-27 2007-09-27 Denu John M O-acetyl-ADP-ribose non-hydrolyzable analogs
SI1971862T1 (sl) * 2006-04-11 2011-02-28 Arena Pharm Inc Postopki uporabe GPR119 receptorja za identificiranje spojin, uporabnih za povečanje kostne mase pri posamezniku
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2012789B1 (en) 2006-04-14 2013-09-25 Prana Biotechnology Limited Method of treatment of age-related macular degeneration (AMD)
US7439372B2 (en) 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
US20090016981A1 (en) 2006-05-03 2009-01-15 Allergan, Inc. Therapeutic compounds
US7476755B2 (en) 2006-05-04 2009-01-13 Allergan, Inc. Therapeutic compounds
AU2007284994B2 (en) 2006-05-09 2010-04-22 Merck Sharp & Dohme Corp. Substituted spirocyclic CGRP receptor antagonists
US7547727B2 (en) 2006-05-22 2009-06-16 Allergan, Inc. Therapeutic cyclopentane derivatives
US7550448B2 (en) * 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
US7553860B2 (en) * 2006-06-14 2009-06-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP2465851A1 (en) 2006-07-05 2012-06-20 Aventis Agriculture 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof
ES2447065T3 (es) 2006-07-10 2014-03-11 Allergan, Inc. Derivados de ciclopentano sustituidos como agentes terapeuticos
KR101433392B1 (ko) 2006-07-14 2014-08-29 케모센트릭스, 인크. 트리아졸릴 페닐 벤젠설폰아마이드
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
US7700627B2 (en) * 2006-07-26 2010-04-20 Allergan, Inc. Therapeutic substituted lactams
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
US7985767B2 (en) * 2006-09-06 2011-07-26 Allergan, Inc. Therapeutic amides
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
EP2076525A2 (en) * 2006-10-06 2009-07-08 Wisconsin Alumni Research Foundation Colchicine neoglycosides and methods for their synthesis and use
CL2007002904A1 (es) 2006-10-10 2008-06-06 Amgen Inc Soc Organizada Bajo Compuestos derivados de pirazolopirimidina; composicion farmaceutica; y uso para tratar una enfermedad seleccionada de diabetes, obesidad, asma y artritis entre otras.
EP1920781B1 (en) 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
US8193373B2 (en) 2006-12-11 2012-06-05 Allergan, Inc. Therapeutic compounds
GB0624757D0 (en) 2006-12-12 2007-01-17 Sosei R & D Ltd Novel compounds
JP2010513569A (ja) 2006-12-19 2010-04-30 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
US20080153808A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
ES2526398T3 (es) 2006-12-22 2015-01-12 Allergan, Inc. Composiciones inhibidoras de la recaptación de serotonina-norepinefrina para tratar el dolor crónico
US20080153881A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153927A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20120083508A1 (en) 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153832A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153880A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153825A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
EP2097689A1 (en) * 2006-12-28 2009-09-09 LG Electronics Inc. Ice making system and method for ice making of refrigerator
JP5226008B2 (ja) 2007-01-11 2013-07-03 ノボ・ノルデイスク・エー/エス ウレアグルコキナーゼアクチベーター
US20100221336A1 (en) * 2007-02-14 2010-09-02 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
CA2679301C (en) 2007-02-28 2015-08-11 University Of Virginia Patent Foundation Lisofylline analogs and methods for use in protecting pancreatic .beta.-cells, treating type 1 diabetes, and treating inflammatory and autoimmune diseases
US8563594B2 (en) * 2007-05-08 2013-10-22 Allergan, Inc. S1P3 receptor inhibitors for treating pain
RS58416B1 (sr) 2007-05-15 2019-04-30 Merial Inc Ariloazol-2-il cijanoetilamino jedinjenja, postupci dobijanja i postupci njihove primene
MX2009012567A (es) 2007-05-22 2010-02-17 Chemocentryx Inc 3-(imidazolil)-pirazolo[3,4-b]piridinas.
WO2008156721A1 (en) 2007-06-20 2008-12-24 Merck & Co., Inc. Diphenyl substituted alkanes
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
KR101969689B1 (ko) 2007-07-12 2019-04-16 케모센트릭스, 인크. 염증의 치료를 위한 ccr2 조절물질로서 융합된 헤테로아릴 피리딜과 페닐 벤젠술폰아마이드
US20100221334A1 (en) * 2007-07-19 2010-09-02 Fink Mitchell P Compositions including leukotriene antagonists and nsaids and methods of using the same
US8222254B2 (en) 2007-08-07 2012-07-17 Prosarix Limited 1, 2, 4-triazole derivatives as serotonergic modulators
US8846053B2 (en) 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
EP2205072B1 (en) 2007-10-15 2013-11-20 The Salk Institute for Biological Studies Methods for treating a variety of diseases and conditions, and compounds useful therefor
US20110160265A1 (en) * 2007-10-18 2011-06-30 Luhrs Lauren M B Method of treating motor disorders with alpha-2b adrenergic receptor agonists
WO2009052072A1 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
WO2009052073A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
EP2222283A2 (en) * 2007-10-29 2010-09-01 University of Massachusetts Yeast cell wall protein (ycwp) encapsulated multilayered nanoparticles for nucleic acid delivery (sirna)
US8063033B2 (en) 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US7956051B2 (en) * 2008-01-24 2011-06-07 Allergan, Inc. Therapeutic amides and related compounds
US8633310B2 (en) * 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7964596B2 (en) 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
US20090233921A1 (en) * 2008-03-11 2009-09-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US7960379B2 (en) * 2008-03-14 2011-06-14 Allergan, Inc. Therapeutic compounds
JP2011514385A (ja) * 2008-03-17 2011-05-06 アラーガン、インコーポレイテッド 炎症を処置するためのs1p3受容体阻害剤
US7960378B2 (en) * 2008-03-18 2011-06-14 Allergan, Inc. Therapeutic compounds
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
US8198318B2 (en) * 2008-03-18 2012-06-12 Allergen, Inc. Therapeutic amides
US7956055B2 (en) * 2008-03-25 2011-06-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
MY150518A (en) * 2008-04-24 2014-01-30 Allergan Inc Substituted gamma lactams as therapeutic agents
US7964634B2 (en) * 2008-04-24 2011-06-21 Allergan, Inc. Therapeutic compounds
US7737140B2 (en) * 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
EP2297084A1 (en) * 2008-04-24 2011-03-23 Allergan, Inc. Therapeutic compounds
AU2009239381A1 (en) 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2009137412A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic compounds
BRPI0912342A2 (pt) * 2008-05-09 2015-10-06 Allergan Inc tiazolidinonas, oxazolidinonas substituídas terapêuticas, e compostos relacionados
AU2009244539B2 (en) 2008-05-09 2014-07-10 Allergan, Inc. Therapeutic substituted hydantoins, and related compounds
WO2009137413A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic cyclopentane derivatives
US7981887B2 (en) * 2008-05-09 2011-07-19 Allergan, Inc. Therapeutic compounds
CA2724972A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic compounds
BRPI0912344A2 (pt) * 2008-05-09 2015-10-13 Allergan Inc derivados terapêuticos de n-aril ou n-heteroaril pirazolidina e pirazolidinona
WO2009142969A1 (en) * 2008-05-20 2009-11-26 Allergan, Inc. Therapeutic lactams
EP2291353B1 (en) * 2008-05-20 2013-09-04 Allergan, Inc. Therapeutic prostaglandin compounds used as ocular hypotensive agents
CA2724605A1 (en) * 2008-05-27 2009-12-03 Allergan, Inc. Prostaglandin prodrugs as hypotensive agents
AU2009257733A1 (en) 2008-06-12 2009-12-17 Merck Sharp & Dohme Corp. Branched 3- and 6-substituted quinolines as CGRP receptor antagonists
US20100022574A1 (en) * 2008-07-28 2010-01-28 EndogenX, Inc. Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
CN105152919A (zh) 2008-07-28 2015-12-16 赛丹思科大学 用于治疗代谢疾病的化合物
EP2320906B1 (en) 2008-08-14 2016-02-24 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
EP2186521A1 (en) 2008-11-14 2010-05-19 Mergemeier Steffen Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
AU2009313920B2 (en) 2008-11-14 2014-10-23 Boehringer Ingelheim Animal Health USA Inc. Enantiomerically enriched aryloazol- 2 -yl cyanoethylamino paraciticidal compounds
WO2010059529A2 (en) 2008-11-19 2010-05-27 Merial Limited Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
CN102223797A (zh) 2008-11-21 2011-10-19 高点制药有限责任公司 金刚烷基苯甲酰胺化合物
TWI457347B (zh) 2008-12-04 2014-10-21 Merial Ltd 二聚合的阿佛菌素(avermectin)及密倍脈心(milbemycin)衍生物
ES2734746T3 (es) 2008-12-22 2019-12-11 Chemocentryx Inc Antagonistas de C5aR
PT2565193E (pt) 2009-01-23 2014-06-05 Rigel Pharmaceuticals Inc Composições e métodos para a inibição da via jak
US8785468B2 (en) 2009-02-13 2014-07-22 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
JP2012518005A (ja) 2009-02-13 2012-08-09 アラーガン インコーポレイテッド 4‐(1‐(3‐(ヒドロキシメチル)‐2‐メチルフェニル)エチル)‐1h‐イミダゾール‐2(3h)‐チオン
EP2395999B1 (en) 2009-02-13 2017-09-13 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
PT2401269E (pt) 2009-02-24 2014-03-11 Merck Canada Inc Derivados de indol como antagonistas de recetor crth2
GB0904044D0 (en) 2009-03-09 2009-04-22 Sosei R & D Ltd The treatment of inflammatory disorders and pain
WO2010103038A1 (en) 2009-03-11 2010-09-16 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
CA2757480A1 (en) * 2009-04-02 2010-10-07 Allergan, Inc. Prostaglandin e receptor antagonists
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
JP2012526133A (ja) 2009-05-05 2012-10-25 ベイポジェニックス インコーポレイテッド 炎症を低減させるための新規揮発性麻酔薬製剤およびその使用法
HUE052685T2 (hu) 2009-05-19 2021-05-28 Neuroderm Ltd Dopa-dekarboxiláz inhibitorok folyamatos adagolására szolgáló készítmények
DK2453890T3 (da) * 2009-07-17 2020-08-17 Allergan Inc Sammensætninger omfattende en kolinesterase-inhibitor til behandling af kognitive lidelser
BR112012002001A2 (pt) 2009-07-28 2016-05-10 Rigel Pharmaceuticals Inc método para tratar uma doença e/ou distúrbio do olho, formulação farmacêutica, e, kit
WO2011019678A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Isothiozoles for treating conditions of the eye
EP2467161A4 (en) * 2009-08-20 2013-03-06 Twi Biotechnology Inc METHOD FOR DIAGNOSTICIZING DIABETES AND DETERMINING THE EFFECTIVENESS OF THERAPIES
AU2010289703A1 (en) 2009-08-26 2012-04-12 Allergan, Inc. Method of treating compulsive disorders with alpha-2B adrenergic receptor agonists
US8455533B2 (en) 2009-09-02 2013-06-04 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US9889182B2 (en) 2009-09-15 2018-02-13 The Regents Of The University Of California Assisted enzyme replacement therapy
EP2480531B1 (en) 2009-09-21 2014-11-05 ChemoCentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators
WO2011041198A1 (en) 2009-09-30 2011-04-07 Transtech Pharma, Inc. Substituted imidazole derivatives for treatment of alzheimers disease
CN102725261B (zh) 2009-11-25 2014-07-30 赛托麦蒂克斯有限公司 花生四烯酸类似物及用其进行镇痛治疗的方法
MX2012006366A (es) 2009-12-04 2012-06-27 Basf Se Compuesto de bis-organoazufre plaguicidas.
EA201401222A1 (ru) 2009-12-17 2015-10-30 Мериал Лимитед Противопаразитарные дигидроазоловые соединения и содержащие их композиции
EP2512467A1 (en) 2009-12-17 2012-10-24 Merial Limited Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles
EP2521721B1 (en) 2009-12-30 2014-10-01 Shanghai Fochon Pharmaceutical Co. Ltd 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
EP2528601A1 (en) 2010-01-26 2012-12-05 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions and methods for prevention and treatment of pulmonary hypertension
US9090584B2 (en) * 2010-01-26 2015-07-28 Allergan, Inc. Therapeutic agents for treatment of ocular hypertension
US8299068B2 (en) * 2010-01-29 2012-10-30 Allergan, Inc. Therapeutically active cyclopentanes
RS58988B1 (sr) 2010-02-03 2019-08-30 Pharma Two B Ltd Formulacije razagilina sa produženim oslobađanjem i njegove upotrebe
GB201002530D0 (en) 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
WO2011103018A1 (en) 2010-02-18 2011-08-25 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基-雜芳基衍生物及其使用方法
US8853212B2 (en) 2010-02-22 2014-10-07 Merck Sharp & Dohme Corp Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
NZ603156A (en) 2010-03-30 2014-10-31 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
UA108641C2 (uk) 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
WO2011133596A1 (en) 2010-04-20 2011-10-27 Institute For Oneworld Health Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
WO2011133600A1 (en) 2010-04-20 2011-10-27 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine sulfonamide derivatives
US20130116284A1 (en) 2010-05-10 2013-05-09 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
KR101860120B1 (ko) 2010-05-26 2018-05-23 브이티브이 테라퓨틱스 엘엘씨 글루코키나아제 활성화제와 병용되는 메트포르민의 용도, 및 메트포르민과 글루코키나아제 활성화제를 포함하는 조성물
EP2582836B1 (en) 2010-06-18 2018-03-07 Taiho Pharmaceutical Co., Ltd. Prpk-tprkb modulators and uses thereof
CA2803920A1 (en) 2010-06-24 2011-12-29 Richard Beard Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
HUE033644T2 (en) 2010-06-24 2017-12-28 Chemocentryx Inc C5AR antagonists
US8859606B2 (en) 2010-07-01 2014-10-14 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US8492424B2 (en) 2010-07-01 2013-07-23 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
EP2588630A4 (en) 2010-07-02 2013-12-25 Univ Virginia Patent Found MOLECULAR GENETIC APPROACH FOR THE TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG INDEPENDENCE
WO2012003145A2 (en) 2010-07-02 2012-01-05 Allergan, Inc. Therapeutic agents for ocular hypertension
US9714238B2 (en) 2010-07-02 2017-07-25 Allergan, Inc. Therapeutic agents for ocular hypertension
CN103201280B (zh) 2010-07-28 2016-08-10 里格尔药品股份有限公司 抑制jak途径的组合物和方法
EP2601187A1 (en) 2010-08-05 2013-06-12 Conrig Pharma ApS Deuterated tandospirone derivatives as 5-ht1a receptor agonists
EP2605771B1 (en) 2010-08-16 2018-04-04 Allergan, Inc. Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
ES2485373T3 (es) 2010-08-20 2014-08-13 Allergan, Inc. Compuestos que actúan en múltiples receptores de prostaglandina proporcionando una respuesta anti-inflamatoria general
WO2012032513A1 (en) 2010-09-07 2012-03-15 Bar-Ilan University Boranophosphate derivatives for the treatment of osteoarthritis
WO2012032524A1 (en) 2010-09-09 2012-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Near infrared fluorescent particles and uses thereof
GB201016880D0 (en) 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
CN105193809B (zh) 2010-10-15 2019-07-16 康特拉医药公司 用于治疗运动障碍的血清素受体激动剂组合物
WO2012058532A2 (en) 2010-10-28 2012-05-03 Yale University Methods and compositions for assessing and treating cancer
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
TWI522355B (zh) 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑
RS57047B1 (sr) 2010-11-15 2018-05-31 Neuroderm Ltd Neprekidno davanje l dope, inhibitora dopa dekarboksilaze, inhibitora katehol-o-metil transferaze i kompozicije za iste
NZ610547A (en) 2010-11-16 2015-07-31 Merial Ltd Novel monensin derivatives for the treatment and prevention of protozoal infections
EP3081651A1 (en) 2010-11-24 2016-10-19 Yale University Compositions and methods for diagnosing and treating diseases and disorders associated with d-dt
US20130296331A1 (en) 2010-11-26 2013-11-07 Technion Research And Development Foundation Ltd. Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
CA2819457A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
EP2648754A4 (en) 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHODS OF INHIBITING THE METASTASIS OF CANCER
GB201020860D0 (en) 2010-12-09 2011-01-26 Univ Wolverhampton Disulfiram formulation and uses thereof
WO2012079172A1 (en) 2010-12-15 2012-06-21 Isotechnika Pharma Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
US8895572B2 (en) 2010-12-22 2014-11-25 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide CGRP receptor antagonists
WO2012093383A1 (en) 2011-01-04 2012-07-12 Radikal Therapeutics Inc. Compositions and methods for treatment of sepsis and related conditions
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
WO2013103384A1 (en) 2012-01-06 2013-07-11 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
HUE051738T2 (hu) 2011-01-07 2021-03-29 Anji Pharma Us Llc Kemoszenzoros receptorligandum-alapú terápiák
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
RS57672B1 (sr) 2011-03-10 2018-11-30 Rigel Pharmaceuticals Inc 2,4 supstituisani pirimidindiamini za upotrebu kod diskoidnog lupusa
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
ES2620521T3 (es) 2011-03-23 2017-06-28 Amgen Inc. Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
JP5991766B2 (ja) 2011-04-06 2016-09-14 ザ メディカル カレッジ オブ ウィスコンシン インク ポキシエイコサトリエン酸類似体およびその製造方法
EP2694465A4 (en) 2011-04-08 2015-03-18 Univ Syddansk SUBSTITUTED ORTHOFLUOR COMPOUNDS FOR THE TREATMENT OF METABOLISM DISEASES
EP2696897A2 (en) 2011-04-11 2014-02-19 Yeda Research and Development Co. Ltd. Albumin binding probes and drug conjugates thereof
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
ES2647072T3 (es) 2011-04-18 2017-12-19 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Niclosamida para el tratamiento de la metástasis en el cáncer
JP6092849B2 (ja) 2011-05-04 2017-03-08 バランス セラピューティックス, インコーポレイテッドBalance Therapeutics, Inc. ペンチレンテトラゾール誘導体
JP2014513692A (ja) 2011-05-09 2014-06-05 ユニバーシティ オブ バージニア パテント ファウンデーション 癌を治療するための組成物及び方法
CA2837382A1 (en) 2011-05-27 2012-12-06 Allergan, Inc. D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders
WO2012163365A1 (en) 2011-06-01 2012-12-06 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
AU2012271562A1 (en) 2011-06-17 2014-01-30 Allergan, Inc. D -serine for the treatment of visual system disorders
US20120329832A1 (en) 2011-06-27 2012-12-27 Jean Delaveau Novel Insect-Repellent Coumarin Derivatives, Syntheses, and Methods of Use
AU2012275435B2 (en) 2011-06-27 2016-07-21 Boehringer Ingelheim Animal Health USA Inc. Amido-pyridyl ether compounds and compositions and their use against parasites
WO2013005216A1 (en) 2011-07-05 2013-01-10 Radikal Therapeutics Inc. Compositions and methods for treatment of renal ischemia-reperfusion injury
RU2014106367A (ru) 2011-07-25 2015-08-27 Аллерган, Инк. N-(ИМИДАЗОЛИДИН-2-ИЛИДЕН)-ГЕТЕРОЦИКЛОПЕНТА[b]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ АЛЬФА 2 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ
US8609658B2 (en) 2011-07-27 2013-12-17 Allergan, Inc. N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
EP2763540A4 (en) 2011-09-09 2015-04-22 Univ Yale COMPOSITIONS AND METHODS FOR EVALUATION AND TREATMENT OF DISEASES AND INFLAMMATORY DISORDERS
CA2848211A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
WO2013041042A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Pyrazole carboxamides as janus kinase inhibitors
US9096598B2 (en) 2011-10-03 2015-08-04 Merck Sharp & Dohme Corp. Azaindoles as Janus kinase inhibitors
KR101688898B1 (ko) 2011-11-03 2016-12-22 타이완 리포솜 캄퍼니 리미티드 소수성 캄프토테신 유도체의 약제 조성물
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
CA2855954C (en) 2011-11-17 2020-09-01 Merial Limited Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof.
TWI531366B (zh) 2011-11-18 2016-05-01 善笙生物科技股份有限公司 牛樟芝在關節炎、軟骨破壞或軟骨細胞死亡的改善或預防的功效
CA2856507C (en) 2011-11-21 2017-03-21 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
US8685959B2 (en) 2011-12-01 2014-04-01 Chemocentryx, Inc. Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists
WO2013082490A1 (en) 2011-12-01 2013-06-06 Chemocentryx, Inc. Substituted anilines as ccr(4) antagonists
BR112014013371B1 (pt) 2011-12-02 2020-04-07 Merial Ltd formulações de moxidectina injetável de ação prolongada e novas formas de cristal de moxidectina
US8993756B2 (en) 2011-12-06 2015-03-31 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
AU2012358978B2 (en) 2011-12-21 2017-10-05 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
WO2013096501A1 (en) 2011-12-21 2013-06-27 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
CA2862263C (en) 2011-12-27 2016-09-06 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
EP2966064A1 (en) 2011-12-27 2016-01-13 Allergan, Inc. Pyrazole-3-carboxylic acid compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
KR102231554B1 (ko) 2012-01-06 2021-03-23 앤지 파마 유에스 엘엘씨 대사 장애를 치료하는 조성물 및 방법
US9073930B2 (en) 2012-02-17 2015-07-07 Merck Sharp & Dohme Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
JP6249966B2 (ja) 2012-02-29 2017-12-20 ケモセントリックス, インコーポレイテッド アザ−アリール1h−ピラゾール−1−イルベンゼンスルホンアミド
NZ629898A (en) 2012-03-23 2016-04-29 Oxigene Inc Compositions and methods for inhibition of cathepsins
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CA2870488A1 (en) 2012-04-16 2013-10-24 Kaneq Pharma Inc. Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
EP2838519B1 (en) 2012-04-17 2017-11-22 University College Dublin National University Of Ireland, Dublin Methods and compounds for treating proliferative disorders and viral infections
EP2838520B1 (en) 2012-04-17 2017-12-13 University College Dublin National University Of Ireland, Dublin Thromboxane receptor antagonists
PL2838517T3 (pl) 2012-04-18 2018-03-30 Contera Pharma Aps Przeznaczony do podawania doustnego preparat farmaceutyczny na potrzeby udoskonalonego leczenia zaburzeń ruchowych
EP2846798B1 (en) 2012-05-09 2018-04-04 Merck Sharp & Dohme Corp. Aliphatic spirolactam cgrp receptor antagonists
EP2846799B1 (en) 2012-05-09 2017-11-15 Merck Sharp & Dohme Corp. Spirolactam cgrp receptor antagonists
WO2013169563A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
WO2013190497A2 (en) 2012-06-21 2013-12-27 Radikal Therapeutics Inc. Compositions and methods for treatment of inflammatory diseases of the lung
EP2874622A4 (en) 2012-07-23 2015-12-30 Merck Sharp & Dohme TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
US20140024621A1 (en) 2012-07-23 2014-01-23 Ms Therapeutics Limited Aminopyridine compounds and their uses
CN104768544B (zh) 2012-08-09 2017-06-16 迪纳米斯治疗公司 包括葡甲胺或其盐的组合物在制备减少或预防甘油三酯水平增加的药物中的应用
WO2014036022A1 (en) 2012-08-29 2014-03-06 Amgen Inc. Quinazolinone compounds and derivatives thereof
JP2015528501A (ja) 2012-09-12 2015-09-28 ライジェル ファーマシューティカルズ, インコーポレイテッド 白斑の治療法
ES2538702T3 (es) 2012-10-19 2015-06-23 Txp Pharma Gmbh Análogos de MSH-alfa y MSH-gamma
US9938281B2 (en) 2012-11-16 2018-04-10 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
EP2922845B1 (en) 2012-11-20 2018-06-20 Merial, Inc. Anthelmintic compounds and compositions and method of using thereof
PL2928474T3 (pl) 2012-12-07 2019-05-31 Chemocentryx Inc Laktamy diazolowe
PT2935227T (pt) 2012-12-21 2017-12-06 Chemocentryx Inc Amidas diazol como antagonistas do recetor ccr1
WO2014113814A1 (en) 2013-01-21 2014-07-24 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US20140213555A1 (en) 2013-01-25 2014-07-31 Rigel Pharmaceuticals, Inc. Compounds and method for treating autoimmune diseases
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
SI2964218T1 (en) 2013-03-05 2018-05-31 Salzman Group, Inc. The prodrugs of multifunctional nitroxide derivatives and their use
MX365206B (es) 2013-03-13 2019-05-27 Neuroderm Ltd Metodo para el tratamiento de la enfermedad de parkinson.
ES2683355T3 (es) 2013-03-14 2018-09-26 Alkermes Pharma Ireland Limited Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
BR112015022340A2 (pt) 2013-03-15 2017-07-18 Verseon Corp método para tratamento ou prevenção de uma doença ou distúrbio relacionado à calicreína em um sujeito, composto, e, composição farmacêutica
CN105209440B (zh) 2013-03-15 2019-07-23 维颂公司 作为凝血酶抑制剂的卤代吡唑
US9051294B2 (en) 2013-04-30 2015-06-09 Allergan, Inc. Therapeutic agents
WO2014194209A1 (en) 2013-05-31 2014-12-04 Allergan, Inc. Substituted cyclopentenes as therapeutic agents
ES2769893T3 (es) 2013-07-02 2020-06-29 Ecoplanet Env Llc Formulaciones de compuestos orgánicos volátiles que tienen actividad antimicrobiana
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US9718818B2 (en) 2013-08-22 2017-08-01 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN104546830B (zh) 2013-10-23 2018-03-09 善笙生物科技股份有限公司 来自牛樟芝菌丝体的化合物及混合物的用途
US9315486B2 (en) 2013-10-29 2016-04-19 Allergan, Inc. Therapeutic cyclopentanols, compositions thereof, and methods for use thereof
CN105873925B (zh) 2013-11-01 2019-09-10 勃林格殷格翰动物保健美国公司 抗寄生物的和杀虫的异噁唑啉化合物
WO2015073344A1 (en) 2013-11-14 2015-05-21 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2015084842A1 (en) 2013-12-02 2015-06-11 Chemocentryx, Inc. Ccr6 compounds
WO2015094864A1 (en) 2013-12-20 2015-06-25 Allergan, Inc. Secondary amines as therapeutic agents
US9365569B2 (en) 2014-01-27 2016-06-14 Allergan, Inc. Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation
RU2696578C1 (ru) 2014-02-05 2019-08-05 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
US11717515B2 (en) 2020-12-22 2023-08-08 Allergan Pharmaceuticals International Limited Treatment of migraine
ES2836325T3 (es) 2014-03-13 2021-06-24 Neuroderm Ltd Composiciones del inhibidor de la dopa descarboxilasa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
WO2015162483A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Alpha- and gamma-msh analogues
WO2015162486A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
DK3134105T3 (da) 2014-04-22 2021-02-22 Txp Pharma Gmbh Peptidanaloger med én eller flere forgrenede aminosyreprober
US9394273B2 (en) 2014-05-15 2016-07-19 Allergan, Inc. Therapeutic prostaglandin receptor agonists
ES2842592T3 (es) 2014-05-19 2021-07-14 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos
US9573926B2 (en) 2014-05-22 2017-02-21 Allergan, Inc. Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use
KR20170010059A (ko) 2014-06-06 2017-01-25 알러간, 인코포레이티드 치료적 화합물로서 신규한 ep4 작용제
US9908923B2 (en) 2014-06-11 2018-03-06 The Medical College Of Wisconsin, Inc. Monomeric CXCL121 peptide and methods of use thereof
WO2016009341A1 (en) 2014-07-14 2016-01-21 Radikal Therapeutics Inc. Thioredoxin mimetic prodrugs and uses thereof
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
WO2016036586A1 (en) 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
AU2015317522A1 (en) 2014-09-17 2017-03-23 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
RU2713653C2 (ru) 2014-10-06 2020-02-06 Кемосентрикс, Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ ИНГИБИТОРАМИ С-С ХЕМОКИНОВОГО РЕЦЕПТОРА 9 (CCR9) И АНТИТЕЛАМИ, БЛОКИРУЮЩИМИ α4β7-ИНТЕГРИН
CA2968090A1 (en) 2014-12-02 2016-06-09 Prana Biotechnology Limited 4h-pyrido[1,2-a]pyrimidin-4-one compounds
CN107406369B (zh) 2014-12-09 2021-01-15 以西结·戈兰 放纵行为调节剂
IL253976B2 (en) 2015-02-20 2024-09-01 Univ Leland Stanford Junior Preparations containing a mixture of allergens and methods of using them
MX2017011000A (es) 2015-02-27 2017-10-20 Verseon Corp Compuestos de pirazol sustituidos como inhibidores de serina proteasa.
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
MX2017014805A (es) 2015-05-19 2018-02-15 Univ Yale Composiciones para el tratamiento de condiciones patologicas de calcificacion y sus metodos de uso.
PE20180529A1 (es) 2015-05-20 2018-03-19 Amgen Inc Agonistas de triazol del receptor apj
ES2916216T3 (es) 2015-05-20 2022-06-29 Boehringer Ingelheim Animal Health Usa Inc Compuestos de depsipéptidos antihelmínticos
ES2776243T3 (es) 2015-06-03 2020-07-29 Medical College Wisconsin Inc Un polipéptido de dímero CCL20 bloqueado modificado por ingeniería
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
JP6921006B2 (ja) 2015-06-15 2021-08-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 老化関連症状を治療するための方法および組成物
JP6837190B2 (ja) 2015-06-16 2021-03-03 エイティーエックスエー セラピューティクス リミテッド トロンボキサン受容体アンタゴニスト
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
NO346258B1 (en) 2015-06-30 2022-05-16 Neurad Ltd Novel breathing control modulating compounds, and methods of making and using same
US11173197B2 (en) 2015-07-07 2021-11-16 Bluewillow Biologics, Inc. Methods and compositions for nanoemulsion vaccine formulations
EP3334706B1 (en) 2015-08-10 2020-09-30 Ramot at Tel-Aviv University Ltd. Pillararenes and uses thereof
US10660884B2 (en) 2015-11-02 2020-05-26 University Of Rochester Phosphonate-chloroquine conjugates and methods using same
WO2017077528A2 (en) 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
CA3003741A1 (en) 2015-11-02 2017-05-11 University Of Rochester Bortezomib conjugates and methods using same
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Cxcr2抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
CA3005142A1 (en) 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same
KR20180102642A (ko) 2016-01-14 2018-09-17 케모센트릭스, 인크. C3 사구체병증을 치료하는 방법
CA3011639A1 (en) 2016-01-20 2017-07-27 Chemocentryx, Inc. 2-oxindole compounds
AU2017216926A1 (en) 2016-02-11 2018-08-02 Eduard Berenshtein Method and pharmaceutical composition for treatment of neurodegeneration
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
WO2017153977A1 (en) 2016-03-08 2017-09-14 Salzman Lovelace Investments, Ltd. Solid formulations of resolvins and uses thereof
EP3439658B1 (en) 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
WO2017177037A1 (en) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
CA3026434A1 (en) 2016-06-03 2017-12-07 Novacyte, Inc. Polymer linkers and their uses
US10036024B2 (en) 2016-06-03 2018-07-31 Purdue Research Foundation siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
CA3029256A1 (en) 2016-06-27 2018-01-04 Chemocentryx, Inc. Immunomodulator compounds
WO2018011181A1 (en) 2016-07-11 2018-01-18 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia
US20210330599A1 (en) 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
WO2018039508A1 (en) 2016-08-25 2018-03-01 Merial, Inc. Method for reducing unwanted effects in parasiticidal treatments
US10449230B2 (en) 2016-10-06 2019-10-22 The Regents Of The University Of California Polymyxin derived cell penetrating scaffolds
AU2017344097A1 (en) 2016-10-14 2019-05-02 Boehringer Ingelheim Animal Health USA Inc. Pesticidal and parasiticidal vinyl isoxazoline compounds
CN110325542A (zh) 2016-11-03 2019-10-11 劳伦斯·I·吴 克罗拉滨的前体药物
CN110114071B (zh) 2016-11-07 2023-07-04 爱彼特生物制药公司 含有取代的吡啶酮的三环化合物以及使用其的方法
EP3541802A1 (en) 2016-11-16 2019-09-25 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP3541789A1 (en) 2016-11-16 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic depsipeptide compounds
KR20240130832A (ko) 2016-11-23 2024-08-29 케모센트릭스, 인크. 국소 분절 사구체경화증의 치료 방법
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
AU2017376398B2 (en) 2016-12-14 2021-07-15 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
EP3601216B1 (en) 2017-03-21 2023-10-25 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy
US20180296588A1 (en) 2017-04-14 2018-10-18 Contravir Pharmaceuticals, Inc. Combination therapy for treating viral infections
DE202017002464U1 (de) 2017-05-09 2017-06-12 St. Lotus Biotech Corp. Pflanzliche Zusammensetzung zur Vorbeugung oder Linderung von ischämischem Schlaganfall
EP3625248A4 (en) 2017-05-18 2021-01-20 The Rockefeller University COMPOSITIONS AND METHODS OF DIAGNOSIS AND TREATMENT OF DISEASES AND DISEASES ASSOCIATED WITH KCNJ5 MUTATIONS
KR20240135687A (ko) 2017-06-20 2024-09-11 임브리아 파마슈티칼스, 인크. 심장 대사의 효율을 증가시키기 위한 조성물 및 방법
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
JP2020530850A (ja) 2017-08-14 2020-10-29 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 殺有害生物および殺寄生生物ピラゾール−イソキサゾリン化合物
AU2018335486B2 (en) 2017-09-25 2024-07-04 Chemocentryx, Inc. Combination therapy using a Chemokine Receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
EP3694504A4 (en) 2017-10-11 2021-07-14 ChemoCentryx, Inc. TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CRC2 ANTAGONISTS
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
EP3716985A1 (en) 2017-11-27 2020-10-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Compounds, compositions, and methods for treating and/or preventing periodontal disease
CN111788185A (zh) 2017-12-22 2020-10-16 凯莫森特里克斯股份有限公司 作为C5a抑制剂的二芳基取代的6,5稠合环化合物
WO2019141957A1 (en) 2018-01-19 2019-07-25 Cado Biotechnology Ivs N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof
US11583545B2 (en) 2018-02-08 2023-02-21 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof
CN112313221A (zh) 2018-02-13 2021-02-02 比托邦制药有限公司 大麻素衍生物和缀合物以及其用途
MA51232A (fr) 2018-02-22 2020-10-07 Chemocentryx Inc Indane-amines utiles en tant qu'antagonistes de pd-l1
WO2019166877A1 (en) 2018-03-02 2019-09-06 Sixfold Bioscience Ltd. Compositions for delivery of cargo to cells
JP2021519334A (ja) 2018-03-26 2021-08-10 クリア クリーク バイオ, インコーポレイテッド ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
KR20200139751A (ko) 2018-04-02 2020-12-14 케모센트릭스, 인크. 융합된-바이사이클릭 C5aR 길항제의 프로드러그
EP3552605A1 (en) 2018-04-11 2019-10-16 Univerzita Palackého V Olomouchi Mcoppb for use as medicament
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
EP3802524A1 (en) 2018-05-29 2021-04-14 Cersci Therapeutics, Inc. Compounds for pain treatment, compositions comprising same, and methods of using same
US20190374607A1 (en) 2018-06-08 2019-12-12 The Medical College Of Wisconsin, Inc. Methods of treating vascular leakage using cxcl12 peptides
EP3820870A1 (en) 2018-07-09 2021-05-19 Boehringer Ingelheim Animal Health USA Inc. Anthelminthic heterocyclic compounds
TW202416959A (zh) 2018-07-27 2024-05-01 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯𠯤,其類似物及使用其之方法
CA3111275A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
CA3110582A1 (en) 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
EP3866794A4 (en) 2018-10-17 2022-07-20 Imbria Pharmaceuticals, Inc. METHODS OF TREATING RHEUMATIC DISEASES USING TRIMETAZIDINE COMPOUNDS
US12030872B2 (en) 2018-10-31 2024-07-09 Merck Sharp & Dohme Llc N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US11773066B2 (en) 2018-11-20 2023-10-03 Boehringer Ingelheim Animal Health USA Inc. Indazolylcyanoethylamino compound, compositions of same, method of making, and methods of using thereof
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
US20200246317A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
US20200246316A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
PE20220281A1 (es) 2019-03-19 2022-02-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos de aza-benzotiofeno y aza-benzofurano como antihelminticos
US11471508B2 (en) 2019-05-09 2022-10-18 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of diabetic peripheral neuropathy
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
WO2020247298A2 (en) 2019-06-06 2020-12-10 Merck Sharp & Dohme Corp. 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
CA3145299A1 (en) 2019-07-08 2021-01-14 Rezolute, Inc. Processes for preparing plasma kallikrein inhibitors
JP2022539830A (ja) 2019-07-10 2022-09-13 ケモセントリックス,インコーポレイティド Pd-l1阻害剤としてのインダン
CN114698370A (zh) 2019-08-08 2022-07-01 里格尔药品股份有限公司 用于治疗细胞因子释放综合征的化合物和方法
ES2970382T3 (es) 2019-08-14 2024-05-28 Rigel Pharmaceuticals Inc Método para bloquear o mejorar el síndrome de liberación de citocinas
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
WO2021189018A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
CA3172088A1 (en) 2020-03-27 2021-09-30 Walter Smith Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
TW202203916A (zh) 2020-03-31 2022-02-01 美商卡默森屈有限公司 使用ccr9抑制劑及抗il—23阻斷抗體治療發炎性腸道疾病的組成物及方法
CN116134144A (zh) 2020-04-23 2023-05-16 Az治疗股份有限公司 细胞的hla-i类mhc消融
EP3901160A1 (en) 2020-04-25 2021-10-27 Nuvamid SA Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
US20230150984A1 (en) 2020-04-24 2023-05-18 Nuvamid Sa Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
WO2021220053A2 (en) 2020-04-27 2021-11-04 Sixfold Bioscience Ltd. Compositions containing nucleic acid nanoparticles with modular functionality
JP2023524111A (ja) 2020-04-30 2023-06-08 エム トビア,アネット サイトカインストームを治療するための組成物および方法
US20230210899A1 (en) 2020-05-28 2023-07-06 Aztherapies, Inc. CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases
JP2023528822A (ja) 2020-05-29 2023-07-06 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 駆虫性複素環式化合物
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
KR20230035601A (ko) 2020-07-07 2023-03-14 에이티엑스에이 테라퓨틱스 리미티드 트롬복산 수용체 길항제 제제
US20230287031A1 (en) 2020-07-17 2023-09-14 Université De Bretagne Occidentale New glycolipids and use thereof as sk3 ion channel modulators
EP4188375A4 (en) 2020-07-29 2024-07-24 Allergan Pharmaceuticals Int Ltd TREATMENT OF MIGRAINE
WO2022029275A1 (en) 2020-08-06 2022-02-10 Nuvamid Sa Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of coronavirus infections and covid-19
CA3187851A1 (en) 2020-08-07 2022-02-10 Guillaume BERMOND Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of an antineoplastic-induced toxicity
WO2022034062A1 (en) 2020-08-12 2022-02-17 Txp Pharma Ag Exendin-4 peptide analogues
KR20230090336A (ko) 2020-10-13 2023-06-21 베타바이브 리미티드 당뇨병 및 관련된 대사성 질환을 치료하기 위한 방법 및 화합물
GB202017255D0 (en) 2020-10-30 2020-12-16 Queens Univ Of Belfast Immunomodulatory agent
GB202017251D0 (en) 2020-10-30 2020-12-16 Queens Univ Of Belfast Neurodegenerative treatment
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11730733B2 (en) 2020-12-10 2023-08-22 Imbria Pharmaceuticals, Inc. Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine
US11793807B2 (en) 2020-12-10 2023-10-24 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
US11969422B2 (en) 2020-12-10 2024-04-30 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine
US12076318B2 (en) 2020-12-10 2024-09-03 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine
ES2974212T3 (es) 2020-12-18 2024-06-26 Nuvamid Sa Derivados de mononucleótidos de nicotinamida en el tratamiento y la prevención de la enfermedad de células falciformes
EP4288041A1 (en) 2021-02-08 2023-12-13 Bausch Health Ireland Limited Amiselimod for preventing, treating, or ameliorating ulcerative colitis
WO2022184685A1 (en) 2021-03-01 2022-09-09 Nuvamid Sa Nicotinamide mononucleotide derivatives and use thereof for the treatment and/or prevention of long covid-19
EP4070799A1 (en) 2021-04-08 2022-10-12 Nuvamid SA Compositions for the improvement of sport performance
EP4079311A1 (en) 2021-04-20 2022-10-26 Nuvamid SA Nmn and derivatives for its use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
EP4079310A1 (en) 2021-04-20 2022-10-26 Nuvamid SA Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
EP4346763A1 (en) 2021-05-31 2024-04-10 Cannabotech Ltd. Compositions comprising a cannabinoid and uses thereof
CA3222984A1 (en) 2021-06-17 2022-12-22 Laurent GARCON Nicotinamide mononucleotide derivatives and use thereof for the treatment of heart failure with preserved ejection fraction
WO2022263676A1 (en) 2021-06-18 2022-12-22 University Of Copenhagen Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
CA3227520A1 (en) 2021-08-02 2023-02-09 Laurent GARCON Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome
JP2024537329A (ja) 2021-10-12 2024-10-10 ベータヴァイヴ・リミテッド 糖尿病及び関連する代謝性疾患を処置するためのペプチド及び断片
US20240116945A1 (en) 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
US20240208987A1 (en) 2022-10-25 2024-06-27 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
WO2024129628A1 (en) 2022-12-14 2024-06-20 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
US12091400B2 (en) 2023-01-20 2024-09-17 Epics Therapeutics Piperidine derivatives as METTL3 inhibitors
WO2024194175A1 (en) 2023-03-17 2024-09-26 Atmosr Adenine derivatives as hsp90 inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US536155A (en) * 1895-03-19 Pill or tablet
US2211485A (en) * 1940-08-13 Effervescent acetyl salicylic acid
US2312381A (en) * 1940-10-24 1943-03-02 Frank J Bickenheuser Medicinal tablet
US3062715A (en) * 1953-11-18 1962-11-06 George S Pfaus Vaginal tablet
GB917456A (en) * 1958-10-30 1963-02-06 Casco Lab Inc Suppository composition and preparation thereof
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
US3136692A (en) * 1961-06-30 1964-06-09 Strong Cobb Arner Inc Effervescent composition containing polyvinylpyrrolidone
GB1093286A (en) * 1965-02-15 1967-11-29 Biorex Laboratories Ltd Improvements in or relating to dosage unit forms for the administration of medicaments and diagnostic agents
FR5391M (ja) * 1965-11-04 1967-10-23
GB1123316A (en) * 1966-12-09 1968-08-14 Wynlit Pharmaceuticals Trust R Improvements in suppositories
US3495001A (en) * 1968-05-27 1970-02-10 Miles Lab Effervescent compositions of acetylsalicylic acid
US3887700A (en) * 1969-11-28 1975-06-03 Aspro Nicholas Ltd Analgesic formulations
US3676549A (en) * 1970-09-30 1972-07-11 Alza Corp Administration of alkali metal salts of salicylamide
US3764668A (en) * 1970-09-30 1973-10-09 Interx Research Corp Compositions of salts of salicylamide
GB1359614A (en) * 1971-04-06 1974-07-10 Dev Et De Rech Soc Fr De Method for the manufacture of effervescent tablets
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150137871A (ko) * 2014-05-30 2015-12-09 디씨에스이엔지 주식회사 회전속도비를 이용하여 회전체내 절삭툴을 제어할 수 있는 오비탈식 파이프 절삭장치

Also Published As

Publication number Publication date
EP0040899B1 (en) 1984-09-12
PT72796B (fr) 1982-03-30
NZ196561A (en) 1983-05-10
IE810765L (en) 1981-10-25
DK152482B (da) 1988-03-07
JPS56167617A (en) 1981-12-23
EP0040899A3 (en) 1982-08-11
ES267593U (es) 1983-05-16
PT72796A (fr) 1981-05-01
ES267593Y (es) 1983-11-16
ES8307092A1 (es) 1983-06-16
ATE9267T1 (de) 1984-09-15
GR73519B (ja) 1984-03-09
ES510822A0 (es) 1983-06-16
DK152482C (da) 1988-08-01
EP0040899A2 (en) 1981-12-02
DE3165901D1 (en) 1984-10-18
IE51216B1 (en) 1986-11-12
US4265874A (en) 1981-05-05
DK184681A (da) 1981-10-26

Similar Documents

Publication Publication Date Title
JPH044293B2 (ja)
US4344929A (en) Method of delivering drug with aid of effervescent activity generated in environment of use
JP2683359B2 (ja) 固体の性質を有する移動可能マトリツクスを含有する投与用製剤
JP3301612B2 (ja) ローディングドースを含む長期配送デバイス
KR100246157B1 (ko) 약물 전달의 지연 활성화 삼투 장치
US4320759A (en) Dispenser with diffuser
US4309996A (en) System with microporous releasing diffusor
JPS60103959A (ja) 浸透性カプセル
US5198229A (en) Self-retaining gastrointestinal delivery device
JPS59167513A (ja) 速効性浸透圧利用薬剤放出システム
JP2925145B2 (ja) 多層投与系
US4235236A (en) Device for dispensing drug by combined diffusional and osmotic operations
JP2567043B2 (ja) 分散用部材を有する有用薬剤投与用製剤
JP3307929B2 (ja) 薬剤の遅延投与のための浸透圧デバイス
DE3625915C2 (de) Abgabevorrichtung zur Freisetzung eines Wirkstoffs
JPH0428242B2 (ja)
JPH0575725B2 (ja)
JPS61249916A (ja) 不活性なコア部を有する浸透圧利用薬剤投与具
JPH0196116A (ja) 急速な薬剤配送と引続く緩徐な薬剤配送からなる投薬形
JPH05502215A (ja) ヒドロゲル駆動要素を含む口腔浸透デバイス
EP0250083B1 (en) Dosage form with means for governing rate of gas formation
JPH0291017A (ja) 溶解度を調節した医薬供給装置
JPS6244249A (ja) 有効剤組成物を反芻動物に投与するための投与デイバイス
IE921885A1 (en) Long-term delivery device including hydrophobic loading dose
JPH11505842A (ja) 高い薬物負荷を有する浸透デバイスと、薬物投与の遅延活性化